IPP Bureau
Tricog raises US$ 8.5 million in series B2 funding
By IPP Bureau - April 25, 2023
The funding will be used to expand the product line for remote patient monitoring and to scale the business across Asia and Africa
Xyall and Indica Labs forge collaboration to transform precision oncology workflows
By IPP Bureau - April 25, 2023
Bridging the gap between histopathology and molecular pathology
Ipca to acquire 33.4% stake in Unichem Labs for Rs 1,034 Cr
By IPP Bureau - April 25, 2023
The business and product range of Ipca and that of Unichem complements each others business and product range
Aster RV Hospital launch needleless injections in South India
By IPP Bureau - April 25, 2023
A special technique of jet injection is used to make vaccination almost painless and totally needleless.
Boehringer Ingelheim inaugurates largest European development centre for biotechnology
By IPP Bureau - April 25, 2023
New high-tech facility in Biberach offers attractive workplaces for more than 500 scientists
Serum & Biocon Biologics agree to restructure equity investment
By IPP Bureau - April 25, 2023
Biocon Biologics Limited will have access to 100 million doses of vaccines annually together with the distribution rights to Serum's Vaccine portfolio
Sun Pharma launches CEQUA, a novel therapy for Dry Eye Disease in India
By IPP Bureau - April 25, 2023
CEQUA is the first dry eye treatment available in India that is delivered with nanomicellar (NCELL) technology
Zydus receives final approval from the USFDA for Metronidazole Topical Cream
By IPP Bureau - April 25, 2023
Metronidazole is an antibiotic used on the skin to treat a certain skin disorder known as rosacea
Indica Labs and Lunit enters into alliance for digital pathology AI workflows
By IPP Bureau - April 25, 2023
Enabling clinical effectiveness via a fully interoperable and integrated digital pathology solution
Huge milestones made towards Zero Malaria goal, says GlobalData
By IPP Bureau - April 25, 2023
Malaria is a life-threatening parasitic infection that is spread by the bites of mosquitoes carrying the Plasmodium parasite
Apollo launches Genomics Institute in Chennai
By IPP Bureau - April 25, 2023
Apollo continues to invest in genomics technology and research for better patient care
Zydus receives final approval from the USFDA for Icosapent Ethyl Capsules
By IPP Bureau - April 24, 2023
Icosapent Ethyl Capsules are indicated as an adjunct to diet to reduce triglyceride levels
USFDA suggests corrective measures to Sun Pharmaceutical’s Mohali facility
By IPP Bureau - April 24, 2023
The USFDA had classified the inspection as "Official Action Indicated" (OAI).
USFDA lifts clinical hold on Phase 3 investigational new drug application for MaaT013
By IPP Bureau - April 24, 2023
This is the first time the Agency has authorized the Phase 3 clinical evaluation in the U.S of a microbiota-based live biotherapeutic based on a pooling technology
Aurisco expands Oligonucleotide capacity
By IPP Bureau - April 24, 2023
The New State-of-Art OligoPilot 2000 solid-phase synthesizer adds cGMP manufacturing capacity to support and accelerate clinical and commercial oligonucleotide programs.
